Adagio Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Adagio Therapeutics, Inc. (NASDAQ:ADGI), now operating as Invivyd, Inc. (NASDAQ:IVVD), is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential, particularly respiratory viruses including SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and measles. The company offers a pipeline of monoclonal antibodies, with lead product PEMGARDA (pemivibart, previously derived from adintrevimab/ADG20), a half-life extended investigational monoclonal antibody authorized by the U.S. FDA under Emergency Use Authorization for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals; additional candidates include VYD2311, an investigational monoclonal antibody optimized for neutralizing contemporary SARS-CoV-2 lineages, VBY329, a potential best-in-class RSV antibody candidate targeting IND readiness in the second half of 2026, and discovery-stage programs for seasonal influenza, measles, and Long COVID via the SPEAR Study Group. Founded in 2020 and headquartered in Waltham, Massachusetts, the company leverages a proprietary integrated discovery platform to engineer antibodies that surpass natural immunity; it primarily serves immunocompromised and high-risk patient populations in the United States, with operations centered in North America. Recent developments include a corporate rebranding to Invivyd in September 2022 to reflect its expanded focus on viral respiratory threats beyond COVID-19, FDA Emergency Use Authorization for PEMGARDA in March 2024, a $125 million public offering priced in November 2025 to support VYD2311 commercialization and pipeline advancement, a $50 million public offering in August 2025 for clinical programs in RSV, measles, and Long COVID research, and selection of RSV candidate VBY329 in 2025; earlier efforts encompassed Phase 2/3 trials of adintrevimab and a February 2025 FDA refusal to expand PEMGARDA's EUA.
Company News
Adagio Therapeutics to Participate in Upcoming Investor Conferences
Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment
Why Adagio Therapeutics Stock Is Soaring Today
Why Adagio Therapeutics Stock Is Soaring Today
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
Trading Penny Stocks? Top Stock Market News for March 30th, 2022
2 Net Current Asset Value Stocks to Consider
Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention
12 biotech stocks to consider buying now as prospects for the sector brighten this year
Top 5 IPOs of 2021
Why Shares of Adagio Therapeutics Soared 25.9% on Thursday
5 Top Biotech Stocks To Watch In January 2022
Adagio Therapeutics Stock (ADGI): Why The Price Went Up Today
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Why Adagio Therapeutics Stock Dived by 13% Today
Adagio Therapeutics Stock (ADGI): Why The Price Surged Over 120% Today
ADGI Stock Alert: 4 Things to Know as Adagio Therapeutics Rockets 100%